Bioinformatics analysis reveals the potential target of rosiglitazone as an antiangiogenic agent for breast cancer therapy

BACKGROUND: Several studies have demonstrated the antitumor activity of rosiglitazone (RGZ) in cancer cells, including breast cancer cells. However, the molecular targets of RGZ in the inhibition of angiogenesis in breast cancer cells remain unclear. This study aimed to explore the potential targets...

Descripción completa

Detalles Bibliográficos
Autores principales: Hermawan, Adam, Putri, Herwandhani
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9482259/
https://www.ncbi.nlm.nih.gov/pubmed/36114448
http://dx.doi.org/10.1186/s12863-022-01086-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9482259/
https://www.ncbi.nlm.nih.gov/pubmed/36114448
http://dx.doi.org/10.1186/s12863-022-01086-2

Ejemplares similares